Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Developer Completes Design Verification of Imaging Device for Bladder Cancer
News Update

Share on Stocktwits


In doing so, it gets one step closer to market approval from U.S. regulators.

Imagin Medical Inc. (IME:CSE; IMEXF:OTCQB) completed design verification of its i/Blue Imaging System as scheduled, on Dec. 31, 2019, the company announced in a news release.

Various tests demonstrated that the main performance characteristics of the device, including radiofrequency emissions and mechanical and electrical safety, met the requisite design specifications, according to Imagin's design partner Optel Inc.

With this development phase finished, Imagin noted that it can now start manufacturing i/Blue on a pilot basis and refine the validation protocols for the device. Some of the units manufactured during the pilot runs will undergo design validation testing. Imagin will submit the resulting data to the U.S. Food and Drug Administration (FDA) as part of the device approval process.

"I couldn't be more pleased about where the company is right now. We're starting off the new year having achieved our 2019 goal of i/Blue units built and verified. These units integrated our innovative design with invaluable feedback from leading urologists at the American Urology Association Meeting last May in Chicago. Now in 2020, we're at a critical point to begin our pilot manufacturing runs and will continue to work with the FDA to determine the final requirements for the i/Blue's market approval.”," Imagin President and CEO Jim Hutchens said in the release.

The company stated that it believes the "i/Blue System, with easy-to-use imaging options, will significantly improve surgeons’ ability to visualize cancerous cells for more accurate resection."


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Imagin Medical. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Imagin Medical. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this interview, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Imagin Medical, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Want to read more about Medical Devices and Life Sciences Tools & Diagnostics investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe